SDGR

Schrodinger, Inc.

$16.49 -0.51 (-3.00%) At close · Jul 7

Market Cap

$1.23B

74,720,724

Equibles Rating blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 16.1 · calm Equity put/call 0.69

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +5%

above

Price vs 50-day avg +17%

above

RSI (14) 59

neutral

MACD trend Positive

52-week position 43%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return +15%

trailing

6-month return −12%

trailing

YTD return −8%

this year

Relative strength −19%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $14 › 200d $16 — 200d above 50d

Institutional flow Accumulating

4 of 228 funds reported for Jun 30 · net +2.2K sh shares · +1 new

Insider flow Distributing

Net -$1.1M over 90 days · 100% sells

Short interest Falling

13.41% of float · ▼ -3.9% MoM · 7.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

228 holders — mid 3-yr range

Squeeze score 67

elevated · 0–100

Fundamentals

Excellent

Revenue growth +23%

Y/Y

Gross margin 56%

contracting

EPS growth +45%

Y/Y

Free cash flow $12.5M

Balance sheet $230.5M

net cash

Quant / Vol

risk profile

Very High

Volatility 52%

annualized · 1-yr

Max drawdown −52%

past year

ATR 6.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next

Next earnings call

Aug 4, 2026 Est · unconfirmed · in 4 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 5, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Guidance & track record what management promised — and delivered

Latest guidance · from the 8-K filed May 5, 2026

fiscal year ending December 31, 2026

ACV (annual contract value) Initiated $218M – $228M

Drug discovery revenue Initiated $55M – $65M

second quarter of 2026

ACV (annual contract value), exclusive of contribution ACV Initiated $19M – $23M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

0 · 4 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+5% Bullish

Price vs 50-day avg

+17% Bullish

RSI (14)

59 Neutral

MACD trend

Positive Bullish

52-week position

43% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $14 › 200d $16 — 200d above 50d

Institutional flow Accumulating

4 of 228 funds reported for Jun 30 · net +2.2K sh shares · +1 new

Insider flow Distributing

Net -$1.1M over 90 days · 100% sells

Short interest Falling

13.41% of float · ▼ -3.9% MoM · 7.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

228 holders — mid 3-yr range

Price context

position in its 52-week range

52-wk low $11 Now $16 · 43% 52-wk high $24

vs 200-day avg +5% vs 50-day avg +17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
ACV	$28.4M	first quarter 2026	—
ACV on a trailing four-quarter basis	$201M	first quarter 2026	—
Software gross margin	69%	first quarter 2026	—
Hosted revenue as percentage of software revenue	23%	Full Year 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Health Information Services — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
SDGR Schrodinger, Inc. this stock	$1.23B	-7.8%	+23.3%	—	13.4%
VEEV Veeva Systems Inc	$30.65B	-13.9%	+28.1%	33.5	4.6%
PMDIY Pro Medicus Ltd./ADR	$15.67B	-9.4%	—	—	0.0%
BTSG BrightSpring Health Services, Inc.	$13.72B	+87.4%	-0.4%	49.8	4.8%
TEM Tempus AI, Inc.	$10.79B	+1.8%	+65.8%	—	21.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

229

% held: 84.3%
Reported: 4 of 228
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

201

View

Short & Settlement

Short Interest Falling

Shares short

10.0M

Days to cover: 7.6d
Change: -406.6K sh

View

Short Volume

Short vol %

52%

As of: Jul 7, 2026

Short Total

View

Fails to Deliver

FTD shares

1.0K

Value: $14.9K
As of: Jun 10, 2026

View

Off-Exchange

Off-exchange %

43.5%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$1.1M

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Financials

Revenue (FY)

$255.9M

Net income (FY): $-103.3M
EPS diluted: $-1.41

View

Filings

SEC Filings

Latest

8-K

Filed: Jun 29, 2026
This year: 10

View

Proposed Sales

Value

$18.9K

Shares: 1.1K
Filed: Jul 1, 2026

View

Earnings & Events

Earnings Calls

Last call

May 5, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
SDGR	-5.2%	+14.7%	-11.5%	+1.5%	-7.8%
SPY	+0.9%	+1.4%	+7.6%	+0.1%	+9.7%
vs SPY	-6.1%	+13.3%	-19.1%	+1.4%	-17.4%

Key facts CIK 1490978 CUSIP 80810D103 13F (30d) 4 filings 4 filers Visit website Investor relations

SDGR

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance